{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T17:34:20Z","timestamp":1785692060963,"version":"3.56.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.pathol.2023.10.013","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T22:11:06Z","timestamp":1702332666000},"page":"214-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues"],"prefix":"10.1016","volume":"56","author":[{"given":"Richard Wing-Cheuk","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie N.Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.10.013_bib1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2023.10.013_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib6","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ijgc-2020-002112","article-title":"British Gynaecological Cancer Society\/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1\/2 variants in ovarian cancer in the United Kingdom","volume":"31","author":"Sundar","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2021.10.072","article-title":"Probability of detecting germline BRCA1\/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis","volume":"164","author":"Witjes","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jmedgenet-2021-108238","article-title":"Practice guidelines for BRCA1\/2 tumour testing in ovarian cancer","volume":"59","author":"Grafodatskaya","year":"2022","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.pathol.2023.10.013_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","article-title":"Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap","volume":"55","author":"McCuaig","year":"2018","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.pathol.2023.10.013_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib12","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2023.10.013_bib14","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.pathol.2023.10.013_bib17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.pathol.2023.10.013_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14737159.2020.1701438","article-title":"A\u00a0profile on the FoundationFocus CDxBRCA tests","volume":"20","author":"Ford","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.pathol.2023.10.013_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.32074\/1591-951X-791","article-title":"In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay","volume":"114","author":"Fumagalli","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.pathol.2023.10.013_bib21","article-title":"In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study","author":"Pepe","year":"2023","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib22","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/CCO.0000000000000660","article-title":"Role of poly (ADP-ribose) polymerase inhibitors beyond BReast CAncer gene-mutated ovarian tumours: definition of homologous recombination deficiency?","volume":"32","author":"Gourley","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib23","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.013_bib24","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.34165","article-title":"The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta-analysis","volume":"151","author":"Atwal","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib25","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2023.10.013_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we stand?","volume":"13","author":"Leary","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib27","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib28","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.013_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molonc.2011.11.010","article-title":"Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response","volume":"6","author":"Chen","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2022.100917","article-title":"Folate receptor as a biomarker and therapeutic target in solid tumors","volume":"47","author":"Young","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib32","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.6004\/jnccn.2017.7066","article-title":"Evolving roles of histologic evaluation and molecular\/genomic profiling in the management of endometrial cancer","volume":"16","author":"Murali","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.pathol.2023.10.013_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.pathol.2023.10.013_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/1940-6207.CAPR-16-0219","article-title":"Clinical challenges associated with universal screening for Lynch syndrome-associated endometrial cancer","volume":"10","author":"Bruegl","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.pathol.2023.10.013_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2023.10.013_bib38","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2019.03.097","article-title":"Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer","volume":"154","author":"Reijnen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/ijgc-2022-003676","article-title":"Biomarker-driven therapy in endometrial cancer","volume":"33","author":"Karpel","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib43","volume":"10","author":"Oaknin","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib44","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1158\/1078-0432.CCR-19-3979","article-title":"FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under Project Orbis","volume":"26","author":"Arora","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.013_bib45","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib46","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib47","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.5858\/arpa.2021-0632-CP","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer","volume":"146","author":"Bartley","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib48","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2015.01.541","article-title":"Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas","volume":"137","author":"McConechy","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.mpdhp.2020.03.002","article-title":"Interpretation of p16, p53 and mismatch repair protein immunohistochemistry in gynaecological neoplasia","volume":"26","author":"Wong","year":"2020","journal-title":"Diagn Histopathology"},{"key":"10.1016\/j.pathol.2023.10.013_bib52","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41379-018-0179-3","article-title":"Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation","volume":"32","author":"Wu","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-018-0125-4","article-title":"Targeted next-generation sequencing in the detection of mismatch repair deficiency in endometrial cancers","volume":"32","author":"Dong","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91974-x","article-title":"Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer","volume":"11","author":"Dedeurwaerdere","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2023.10.013_bib55","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ijgc-2022-004026","article-title":"Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer","volume":"33","author":"Hill","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib56","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib57","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.013_bib58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib60","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pathol.2022.11.004","article-title":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma","volume":"55","author":"Talia","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2023.10.013_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib63","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2022.09.006","article-title":"HER2 in uterine serous carcinoma: testing platforms and implications for targeted therapy","volume":"167","author":"Klc","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib66","first-page":"1","article-title":"Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options","volume":"40","author":"MacKay","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.pathol.2023.10.013_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12957-015-0619-1","article-title":"Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2015","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib69","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.3802\/jgo.2019.30.e13","article-title":"The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification","volume":"30","author":"Guan","year":"2019","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib70","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib71","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib72","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.5858\/arpa.2016-0450-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium","volume":"141","author":"Longacre","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib73","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ajog.2021.05.007","article-title":"Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer","volume":"225","author":"van Weelden","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.pathol.2023.10.013_bib74","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ejca.2014.09.003","article-title":"Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions","volume":"50","author":"Tangen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134969","article-title":"Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-A expression compared to matched primary tumors","volume":"10","author":"Bartosch","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2023.10.013_bib76","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/ijgc-2020-002256","article-title":"p53abn endometrial cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","volume":"31","author":"Jamieson","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211035959","article-title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","volume":"13","author":"Jamieson","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PGP.0000000000000674","article-title":"Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma","volume":"40","author":"Brett","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib80","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib81","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib82","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib83","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib84","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib85","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib87","first-page":"402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.pathol.2023.10.013_bib88","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib89","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1158\/1078-0432.CCR-18-0266","article-title":"Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues","volume":"24","author":"Van Gool","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.013_bib90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2019.10.028","article-title":"Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer","volume":"156","author":"Stasenko","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2020.07.102","article-title":"POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women","volume":"159","author":"He","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib92","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib93","article-title":"Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition","volume":"6","author":"Eggink","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pathol.2023.10.013_bib94","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/PGP.0000000000000710","article-title":"POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting","volume":"40","author":"Casey","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib97","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/PGP.0000000000000898","article-title":"Targeted molecular testing in endometrial carcinoma: validation of a clinically driven selective ProMisE testing protocol","volume":"42","author":"Talhouk","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib98","series-title":"BAGP guidance on POLE NGS testing in endometrial carcinoma","author":"Singh","year":"2022"},{"key":"10.1016\/j.pathol.2023.10.013_bib99","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00428-021-03176-5","article-title":"Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma","volume":"479","author":"Ruz-Caracuel","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2023.10.013_bib100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajcp\/aqy178","article-title":"Immunohistochemical nuclear expression of \u03b2-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer","volume":"151","author":"Travaglino","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib101","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PGP.0000000000000583","article-title":"Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma","volume":"39","author":"Costigan","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib102","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djt144","article-title":"L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation","volume":"105","author":"Zeimet","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.pathol.2023.10.013_bib103","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.805613","article-title":"Current prognostic and predictive biomarkers for endometrial cancer in clinical practice: recommendations\/proposal from the Italian Study Group","volume":"12","author":"Zannoni","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib105","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer","volume":"11","author":"Disis","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0000000000000701","article-title":"PD-L1 interpretation in cervical carcinomas: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Mills","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib107","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer \u2013 update 2023","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib108","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib109","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.21037\/atm-20-2656","article-title":"Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer","volume":"8","author":"Borcoman","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib110","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib111","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.013_bib112","article-title":"Management and care of patients with invasive cervical cancer resource-stratified guideline expert panel. Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update","volume":"8","author":"Chuang","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib113","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/PO.20.00412","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","volume":"5","author":"Prince","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib114","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41379-021-00780-3","article-title":"Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/1471-0528.13071","article-title":"HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis","volume":"122","author":"Rodr\u00edguez-Carunchio","year":"2015","journal-title":"BJOG"},{"key":"10.1016\/j.pathol.2023.10.013_bib116","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41379-019-0249-1","article-title":"HPV-negative tumors of the uterine cervix","volume":"32","author":"Nicol\u00e1s","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-2021-003014","article-title":"Human papillomavirus-independent cervical cancer","volume":"32","author":"Fernandes","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2023.10.013_bib118","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41379-019-0360-3","article-title":"Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix","volume":"33","author":"Nicol\u00e1s","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib119","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib120","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1158\/1078-0432.CCR-17-1302","article-title":"Genomic characterization of vulvar (pre)cancers identifies distinct molecular subtypes with prognostic significance","volume":"23","author":"Nooij","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.013_bib121","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ygyno.2020.09.024","article-title":"Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes","volume":"159","author":"Kortekaas","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100145","article-title":"Classification of vulvar squamous cell carcinoma and precursor lesions by p16 and p53 immunohistochemistry: considerations, caveats, and an algorithmic approach","volume":"36","author":"Yang","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib123","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib124","article-title":"Prevalence of human papillomavirus and its prognostic value in vulvar cancer: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2023.10.013_bib125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/PGP.0000000000000620","article-title":"HPV-independent vulvar squamous cell carcinoma is associated with significantly worse prognosis compared with HPV-associated tumors","volume":"39","author":"Allo","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib126","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/PGP.0000000000000263","article-title":"p16 immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases","volume":"35","author":"Cheng","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib127","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fonc.2019.00891","article-title":"Overexpression of p16INK4a serves as prognostic marker in squamous cell vulvar cancer patients treated with radiotherapy irrespective of HPV-status","volume":"9","author":"Arians","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2023.10.013_bib128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/his.14925","article-title":"Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features","volume":"83","author":"Carreras-Dieguez","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2023.10.013_bib129","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41379-020-0524-1","article-title":"Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status","volume":"33","author":"Tessier-Cloutier","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.10.013_bib130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/his.14109","article-title":"Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma","volume":"77","author":"Kortekaas","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2023.10.013_bib131","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41379-020-0527-y","article-title":"p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns","volume":"33","author":"Thompson","year":"2020","journal-title":"Mod Pathol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:32:14Z","timestamp":1758472334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302523003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0031302523003100"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.013","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}